Table 2.
Bone turnover marker results at baseline, 4 and 8 weeks
| Bone biomarker | Time | Teriparatide group (n = 6) | Placebo group (n = 7) | P value | ||||
|---|---|---|---|---|---|---|---|---|
| Mean | Min | Max | Mean | Min | Max | |||
| Serum ALP (IU/L) | Baseline | 58.3 | 39.0 | 85.0 | 60.1 | 36.0 | 112.0 | 0.95 |
| 4 weeks | 63.3 | 45.0 | 94.0 | 62.7 | 42.0 | 105.0 | 0.43 | |
| 8 weeks | 61.5 | 61.2 | 90.0 | 63.0 | 41.0 | 107.0 | 0.52 | |
| Serum P1NP (µg/L) | Baseline | 40.1 | 15.8 | 85.6 | 42.4 | 19.4 | 57.8 | 0.33 |
| 4 weeks | 88.5 | 47.0 | 197.2 | 43.9 | 24.2 | 62.7 | 0.003a | |
| 8 weeks | 103.1 | 61.2 | 245.1 | 47.5 | 26.1 | 76.6 | 0.005a | |
| Serum OC (ng/mL) | Baseline | 5.8 | 0.6 | 13.0 | 7.9 | 3.6 | 10.1 | 0.43 |
| 4 weeks | 12.6 | 1.8 | 24.3 | 9.2 | 5.3 | 12.8 | 0.027a | |
| 8 weeks | 16.8 | 0.9 | 30.8 | 9.6 | 6.0 | 12.7 | 0.003a | |
| Serum CTX (ng/mL) | Baseline | 0.43 | 0.26 | 0.64 | 0.54 | 0.28 | 1.28 | 0.44 |
| 4 weeks | 0.61 | 0.19 | 1.41 | 0.43 | 0.29 | 0.61 | 0.43 | |
| 8 weeks | 0.66 | 0.31 | 1.28 | 0.50 | 0.31 | 0.80 | 0.28 | |
| Urine NTX (nMBCE/mMCr) | Baseline | 161.7 | 40.0 | 371.0 | 356.9 | 94.0 | 695.0 | 0.12 |
| 4 weeks | 205.3 | 83.3 | 547.0 | 384.4 | 34.0 | 772.0 | 0.78 | |
| 8 weeks | 213.3 | 31.0 | 540.0 | 524.4 | 110.0 | 1492.0 | 0.62 | |
P1NP, N-terminal propeptide of type 1 collagen; OC, osteocalcin; CTX, C-telopeptide of type 1 collagen; urine NTX, N-telopeptide of type 1 collagen, corrected for mM creatinine.
a
Bone formation markers, P1NP and OC, were significantly different (p-value < 0.05) at 4 and 8 weeks.